The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Oxazolidinone Structure–Activity Relationships Leading to Linezolid
Abstract
The development of bacterial resistance to currently available antibacterial agents is a growing global health problem. Of particular concern are infections caused by multidrug‐resistant Gram‐positive pathogens which are responsible for significant morbidity and mortality in both the hospital and community settings. A number of solutions to the problem of bacterial resistance are possible. The most common approach is to continue modifying existing classes of antibacterial agents to provide new analogues with improved attributes. Other successful strategies are to combine existing antibacterial agents with other drugs as well as the development of improved diagnostic procedures that may lead to rapid identification of the causative pathogen and permit the use of antibacterial agents with a narrow spectrum of activity. Finally, and most importantly, the discovery of novel classes of antibacterial agents employing new mechanisms of action has considerable promise. Such agents would exhibit a lack of cross‐resistance with existing antimicrobial drugs. This review describes the work leading to the discovery of linezolid, the first clinically useful oxazolidinone antibacterial agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brickner, S. J., Hutchinson, D. K., Barbachyn, M. R., Manninen, P. R., Ulanowicz, D. A., Garmon, S. A., Grega, K. C., Hendges, S. K., Toops, D. S., Ford, C. W., et al. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9509556 · Cited by 582
Self-citationEmergence of Drug-Resistant Pneumococcal Infections in the United States
Breiman, R. F. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510470035031 · Cited by 562
The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria
Swaney, S. M., Aoki, H., Ganoza, M. C., & Shinabarger, D. L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3251 · Cited by 555
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
Self-citationMechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions
Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H., Melchior, E. P., Swaney, S. M., Dunyak, D. S., Demyan, W. F., & Buysse, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2132 · Cited by 384
Structure-activity relationships of the fluoroquinolones
Chu, D. T., & Fernandes, P. B. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.2.131 · Cited by 284
Lin, A. H., Murray, R. W., Vidmar, T. J., & Marotti, K. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2127 · Cited by 261
Ho, P.-L., Que, T.-L., Tsang, D. N.-C., Ng, T.-K., Chow, K.-H., & Seto, W.-H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1310 · Cited by 241
World-wide development of antibiotic resistance in pneumococci
Appelbaum, P. C. (1987) · European Journal of Clinical Microbiology · doi:10.1007/bf02013089 · Cited by 181
The in-vitro activity of linezolid (U-100766) and tentative breakpoints
Wise, R. A., Andrews, J. M., Boswell, F. J., & Ashby, J. P. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.6.721 · Cited by 149
Ford, C. W., Hamel, J. C., Wilson, D. M., Moerman, J. K., Stapert, D., Yancey, R. J., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.6.1508 · Cited by 140
Self-citationMechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis
Eustice, D. C., Feldman, P., Zajac, I., & Slee, A. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.8.1218 · Cited by 118
Kaatz, G. W., & Seo, S. M. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.799 · Cited by 112
Dailey, C. F., Dileto, C. L., Buchanan, L. V., Oramas-Shirey, M. P., Batts, D. H., Ford, C. W., & Gibson, J. K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.8.2304-2308.2001 · Cited by 91
Self-citationJorgensen, J. H., McElmeel, M. L., & Trippy, C. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.465 · Cited by 71
Johnson, A. P., Warner, M., & Livermore, D. M. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.2.225 · Cited by 67
von Eiff, C., & Peters, G. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.4.569 · Cited by 62
Efficacy of linezolid in a staphylococcal endocarditis rabbit model
Oramas-Shirey, M. P., Buchanan, L. V., Dileto-Fang, C. L., Dailey, C. F., Ford, C. W., Batts, D. H., & Gibson, J. K. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.3.349 · Cited by 50
Self-citation
Cited by
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
Meanwell, N. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1013693 · Cited by 2,854
Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules
Kirk, K. L. (2006) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2006.06.007 · Cited by 900
Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?
von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., & Häbich, D. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600350 · Cited by 672
Carbon dioxide utilization with C–N bond formation: carbon dioxide capture and subsequent conversion
Yang, Z.-Z., He, L.-N., Gao, J., Liu, A.-H., & Yu, B. (2012) · Energy & Environmental Science · doi:10.1039/c2ee02774g · Cited by 520
Targeting Antibiotic Resistance
Chellat, M. F., Raguž, L., & Riedl, R. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201506818 · Cited by 487
Metadata
- Authors
- Barbachyn, M. R., & Ford, C. W.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2003-05-08
- Volume
- 42
- Issue
- 18
- Pages
- 2010-2023
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2168281308
- Cited by
- 553
- References
- 18
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.